{
    "nct_id": "NCT05396781",
    "official_title": "Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening: A Clinical Study in Brazil",
    "inclusion_criteria": "* Outpatients undergoing routine (standard of care) Lugol's chromoendoscopic screening for squamous cell neoplasia will be eligible for enrollment including patients with known history of head/neck squamous cell cancer.\n* Patients must be >18 years old and able to give informed consent.\n* For the provider surveys and interviews, all providers (clinicians, trainees) who are working on the project will be eligible to participate.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 64 Years",
    "exclusion_criteria": "* Allergy or prior reaction to the fluorescent contrast agent proflavine\n* Patients who are unable to give informed consent\n* Known advanced squamous cell carcinoma of the distal esophagus, or dyplastic/suspected malignant esophageal lesion greater than or equal to 2cm in size not amenable to endoscopic therapy\n* Patient unable to undergo routine endoscopy with biopsy\n* Women who are pregnant or breastfeeding\n* Prothrombin time greater than 50% of control; Partial Thromboplastin Time greater than 50 sec, or International Normalized Ratio greater than 2.0\n* inability to tolerate sedated upper endoscopy due to cardio-pulmonary instability or other significant medical issues\n* Providers will be excluded if they decline participation or otherwise opt out of the proposed research project.",
    "miscellaneous_criteria": ""
}